| Institution: | 1. Weifang People’s Hospital, 261000 Weifang, China;2. School of Basic Medicine, Weifang Medical University, 261053 Weifang, China;3. Department of Pharmacology, School of Medicine, Southeast University, 210009 Nanjing, China;1. Department of Biochemistry, Faculty of Science, The Maharaja Sayajirao University of Baroda, Vadodara 390002, Gujarat, India;2. C. G. Bhakta Institute of Biotechnology, Uka Tarsadia University, Tarsadi, Surat 394350, Gujarat, India;1. Pharmaceutical Sciences Research Division, Department of Pharmacy, Medical Supplies Centre of PLA General Hospital, Beijing, China;2. Medical School of Chinese PLA, Beijing, China;3. Chinese People''s Armed Police Force Hospital of Beijing, Beijing, China;1. Postgraduate Program in Genetics, Department of Genetics, Federal University of Paraná (UFPR), Centro Politécnico, Jardim das Américas, 81531-990 Curitiba, PR, Brazil;2. Human Molecular Genetics Laboratory, Genetics Department, Federal University of Paraná (UFPR), Centro Politécnico, Jardim das Américas, 81531-990 Curitiba, PR, Brazil;1. Department of Molecular Biomedicine, Centro de Investigación y de Estudios Avanzados del I.P.N, 07360 Mexico City, Mexico;2. Department of Clinical Research, Instituto Nacional de Medicina Genómica, 14610 Mexico City, Mexico;3. Department of Biochemistry, Centro de Investigación y de Estudios Avanzados del I.P.N, 07360 Mexico City, Mexico;4. Myeloid Cell Laboratory, Centro de Investigaciones Biológicas, CSIC, 28040 Madrid, Spain;1. Tianjin Medical University, Tianjin 300070, China;2. Department of Tissue Repair and Regeneration, PLA General Hospital and PLA Medical College, Beijing 100853, China;4. PLA Key Laboratory of Tissue Repair and Regenerative Medicine and Beijing Key Research Laboratory of Skin Injury, Repair and Regeneration, Beijing 100048, China;5. Research Unit of Trauma Care, Tissue Repair and Regeneration, Chinese Academy of Medical Sciences, 2019RU051, Beijing 100048, China;6. Plastic and Maxillofacial Surgery Department, Second Affiliated Hospital of Chongqing Medical University, Chongqing, China;1. Dept. of Microbiology, Faculty of Sciences, Zanjan Branch, Islamic Azad University, Zanjan, Iran;2. Nanobiotechnology Research Center, Zanjan Branch, Islamic Azad University, Zanjan, Iran |
| Abstract: | PLPPs (Phospholipid phosphatases) are widely expressed in different human tissues, regulate cell signal transduction, and are overexpressed in cancers such as gliomas, pancreatic adenocarcinoma, lung adenocarcinoma, and so on. As a member of the PLPP family, PLPP2 (phospholipid phosphatase 2) plays a vital role in the occurrence and development of breast cancer, but its mechanism is still unclear. Our research found that PLPP2 was overexpressed in breast cancer, and the higher expression level of PLPP2 showed a worse prognosis for breast cancer patients. Further analysis showed that overexpression of PLPP2 affected the expression of CDC34 (cell-division cycle 34), LSM7 (Like-Smith 7), and SGTA (small glutamine-rich tetratricopeptide repeat-containing protein alpha) through EMT (epigenetic-mesenchymal transition) related pathways to promote the occurrence and development of breast cancer. In vitro, silencing PLPP2 significantly reduced the proliferation, invasion, and migration abilities of human breast cancer cells MDA-MB-231. ER+ is a common subtype of breast cancer. Furthermore, we found that the overexpression of PLPP2 was significantly related to the poor prognosis of ER+ breast cancer. These results indicate that PLPP2 has value as a potential therapeutic target for breast cancer, especially for ER+ breast cancer. |
